Overview
The Effect Of Tafamidis For The Transthyretin Amyloid Polyneuropathy Patients With V30M Or Non-V30M Transthyretin
Status:
Completed
Completed
Trial end date:
2014-02-01
2014-02-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
Tafamidis has been developed as an oral specific stabilizer of transthyretin tetramer.Phase:
Phase 3Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Pfizer
Criteria
Inclusion Criteria:- Transthyretin amyloid polyneuropathy with V30M or non-V30M transthyretin mutation.
- Subject had amyloid documented by biopsy in accordance with institutional site
standard of care.
Exclusion Criteria:
- Primary amyloidosis and secondary amyloidosis.
- History of liver transplant.